tgfa-pe38 immunotoxin
Recombinant proteinexperimental
Clinical trial activity
1 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2004 (NCT00074334)
Timeline
2000s
- Jan 1, 2004
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- Protransforming growth factor alphaBINDING AGENT
TGFA binding agent
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- PE38
Oral
No
Parenteral
No
Topical
No
Also known as
- tgfa-pe38 immunotoxin
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00074334 | Phase 1/Phase 2 (Phase 2) | May 1, 2004 | Children's National Medical Center, National Cancer Institute (NCI), Pediatric Brain Tumor Consortium |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Children's National Medical Center | Academic/Hospital | 1 | 0 | 1 | 2004 |
| National Cancer Institute (NCI) | Government | 1 | 0 | 1 | 2004 |
| Pediatric Brain Tumor Consortium | Academic/Hospital | 1 | 1 | 1 | 2004 |
3 organizations
Page 1 / 1